BACKGROUND: Recent reports of new and important roles for serotonin (5-hydroxytryptamine, 5-HT) in the periphery have substantially increased interest in measuring peripheral serotonin. Nearly all circulating serotonin is found within platelets and this pool has been assessed by measuring serotonin in whole blood or in platelet-rich plasma. Measurement of the much smaller but potentially critically important pool of human free plasma serotonin in platelet-poor plasma (PPP) has proven much more difficult, with a wide range of reference values reported.
There is a clear and pressing need for reference materials for the measurement of plasma (PPP) serotonin.
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Serotonin (5-hydroxytryptamine, 5-HT) is an important central nervous system neurotransmitter and neuromodulator, and nearly all central nervous system neurons receive afferents from serotonergic neurons that have cell bodies in the raphe nuclei of the brain stem (1, 2 ) . Most peripheral serotonin is found in the enterochromaffin cells of the intestine and in the platelet; determination of urinary concentrations of the serotonin metabolite 5-hydroxyindole-acetic acid is useful in carcinoid diagnosis (3 ) , whereas platelet serotonin has been measured in the assessment of platelet storage pool disease (4 ) and the bioeffect of serotonin reuptake inhibitors (5 ) , and as a potential proxy of central serotonin.
Recent reports of new and important roles for serotonin in the periphery have served to increase interest in circulating serotonin (6 ) . Relevant findings include the possible requirement for maternally derived serotonin in mammalian embryogenesis (7 ) , the role of gut-derived serotonin in bone growth regulation (8 ) , the roles of peripheral serotonin in liver regeneration (9 ) and mammary gland development (10 ) , the implication that serotonin plays a role in fenfluramine cardiac valvulopathy, and the importance of pancreatic extracellular serotonin in the control of insulin secretion (11 ) . Nearly all circulating serotonin is found sequestered within the dense granules of the platelet and is physiologically active only after platelet activation, degranulation, and release into the plasma. This platelet storage pool has been assessed by measuring serotonin in whole blood or in platelet-rich plasma. The much smaller pool of free (extraplatelet) plasma serotonin is accessible to sites of action and receptors, and may be critically important in the processes mentioned above. Assessing this extraplatelet plasma pool has proven very difficult. Researchers from various fields including gastroenterology, hematology, endocrinology, and neuropsychiatry have attempted to estimate the free plasma pool by measuring serotonin concentrations in platelet-poor plasma (PPP).
In an attempt to determine the best estimate of true PPP serotonin concentrations in humans, we have carried out a systematic literature search of previous reports of PPP serotonin to characterize the available data. We hope that an improved and more complete assessment of circulating serotonin will help elucidate the varied crucial roles for peripheral serotonin.
Methods

LITERATURE SEARCH
We performed the search by using scientific literature databases, including PubMed, provided by NCBI (the National Center for Biotechnology Information), SciVers ScienceDirect, and OVID. Relevant publications were found by searching for "platelet-poor plasma," "PPP" or "platelet-depleted plasma" "PDP", "free plasma," or "plasma" combined with "5-HT," "5-hydroxytryptamine," or "serotonin." The bibliographies of identified reports were also searched for additional relevant publications. Information extracted from identified publications included details of the method used to prepare PPP and to determine serotonin concentrations, reported values (mean, median, range) of free plasma, and PPP serotonin SD or SE. In 6 instances only median values were reported and in those cases the median was treated as the mean. Two reports (72, 101 ) presented values of Ͻ1.0 nmol/L and Ͻ3.5 nmol/L, which were "below the detection limit"; these threshold values were treated as though they were mean values for the purposes of the summary statistics.
Results
A total of 101 reports that included concentrations of PPP serotonin in healthy controls were found, and the data from these reports were included in the summary statistical analyses (12-112 ) (see Table 1 ). The individual means from each report are displayed in Fig. 1 . The range of reported concentrations was 0.6 to 179 nmol/L, with a mean of 31.6 nmol/L and an SD of 38.9 nmol/L. The calculated median was 14.8 nmol/L and the skewness was high (ϩ1.98). The first quartile concentrations ranged from 0.6 to 6.5 nmol/L, the second quartile from 6.7 to 14.8 nmol/L, the third quartile from 15.0 to 39.6 nmol/L, and the fourth quartile from 39.7 to 179.0 nmol/L. The inset in Fig. 1 presents the individual group means from the 51 reports that included PPP serotonin concentrations below the median of 14.8 nmol/L. In Fig. 2 , the reported mean PPP serotonin values are plotted vs year of publication, whereas in Fig. 3 the reported mean PPP serotonin values are plotted vs the number of samples measured. In Table 2 , the reports of human PPP serotonin have been grouped according to analytical methods employed.
The methods used for the preparation of PPP in reports that included mean concentrations of PPP serotonin of Ͻ3 nmol/L are briefly described in Table 3 .
Discussion
A systematic literature search revealed 101 reports of PPP serotonin concentrations in healthy humans. As seen in Fig. 1 , an extremely wide range of concentrations has been reported. There was no marked modality in the distribution of the values, although several apparent discontinuities could be seen. As seen in Fig.  2 , there has been a slight downward trend in reported values over time (r ϭ Ϫ0.26). However, there has been very little improvement in the wide range or discrepant nature of reported mean PPP serotonin concentrations over the years. It should be noted that the increase in the number of published reports beginning in the mid1980s was mainly attributable to the increased availability of HPLC methods. In Fig. 3 , the reported mean PPP serotonin values are plotted vs the number of samples measured. This funnel-type plot indicates that there was some tendency for larger studies to report lower values. This trend appeared to be attributable largely to such studies being somewhat more likely to carefully examine PPP preparation parameters and to more often use more specific analytical methods.
The preanalytical and analytical factors that potentially affected the reported concentrations of PPP serotonin included (a) the venipuncture procedure, including site, needle gauge, syringe, and anticoagulant; (b) the centrifugation process, including tube type, force, time, temperature, and specific plasma portion removed; (c) the recovery of serotonin during all phases of sample handling; (d) the sample preparation procedure including any prepurification; (e) the separation or chromatographic method; and (f) the specificity and sensitivity of the detection method. The preanalytical factors (a) and (b) above are mainly concerned with minimizing platelet contamination and the release of serotonin from the platelets. The analytical factors are crucial given the extremely low concentrations of plasma serotonin present when care is taken to minimize release.
As seen in Table 2 , radioenzymatic and mass spectrometric methods tended to provide the lowest estimates of PPP serotonin. As expected given the relatively nonselective nature of the extraction procedures used, early spectrofluorometric methods gave the highest PPP serotonin values. The wide range of PPP serotonin values reported when HPLC analytical methods were used (even when similar PPP preparation procedures were employed and recovery was accounted for) is somewhat surprising and is evidence of nonspecificity. It appears that researchers have often overly relied Continued on page XX Reviews on retention time and detector selectivity to provide sufficient specificity when using a combination of chromatographic and spectral methods. It is often assumed that lower concentrations are more accurate estimates of biomedical analytes. Underlying this assumption is the great potential for having interfering species in the complex matrices typically encountered in biomedical analyses. Two particularly relevant examples of this assumption that are being borne out in practice are the determination of human 
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Reviews plasma histamine (113 ) and epinephrine (114, 115 ) . It should be noted that the assumption is true only if appropriate recovery studies have been performed; recovery studies are especially important when measuring serotonin because of its demonstrated lability with respect to oxidative and enzymatic degradation. The potential for erroneously high values is substantially increased when PPP serotonin is assayed, owing to the difficulty of preparing PPP without causing release of platelet serotonin and without platelet contamination. A variety of blood-drawing and samplehandling protocols have been used to isolate PPP. Lower concentrations of PPP serotonin [average reported mean for the 5 cited studies was 1.94 (1.09) nmol/L] were reported for studies that included careful examination of the effect of PPP preparation parameters on observed PPP serotonin concentrations (33, 60, 62, 66, 93 ) . Conversely, if it is assumed that lower PPP serotonin values reflect a more accurate estimation of serotonin present in the prepared PPP sample, the effect of sample preparation parameters would be best examined in studies for which lower PPP serotonin concentrations were reported. When the PPP preparation methods used in the reported studies with PPP serotonin values of Ͻ3 nmol/L were examined (see Table 3 ), it appeared that a double centrifugation was not necessary, that centrifugation at room temperature or at 4°C was suitable, and that removal of the PPP sample only from the midportion of the plasma column probably would be recommended. This statement is tentative and is based on a consideration of the information presented in Table 3 and the more detailed information presented in the 5 cited studies in which sample preparation parameters were carefully studied. The work of Beck and colleagues (60 ) seems to be particularly worthwhile in this regard, given its thorough execution and well-described analytical methodology.
The group of 5 reports (60, 66, 67, 101, 109 ) with concentrations around 1 nmol/L appear to us to likely offer the best estimate of human PPP serotonin concentration. We make this assertion on the bases mentioned, including the care taken in the relevant studies in regard to sample preparation and the specificity of the employed analytical methodology, as well as the available close historical parallels. All other values appeared to be too high, because of the presence of either artifactual (platelet-derived) serotonin or insufficiently selective analytical methods, or both. Methods that yielded reported concentrations of PPP serotonin of up to 3 nmol/L might still be useful for certain purposes, such as those for which associated additive or multiplicative analytical errors were consistent across samples, consistent amounts of platelet-derived serotonin were present, Reviews or large changes in PPP serotonin were expected. However, nearly all (88 of 101) of the prior reportsthose for which values of Ͼ3 nmol/L were reported-are probably best rejected, given the apparent magnitude of their error. Although rejection of most of the published work represents a tremendous amount of wasted effort, acceptance of the higher erroneous reported values entails the great risk that future investigators will reach erroneous conclusions and contribute to misguided follow-up research.
This systematic review reveals 2 important problems. The first has to do with the apparent difficulty encountered when researchers have attempted to measure low concentrations of PPP serotonin. As mentioned, the measurement of extremely low concentrations of PPP serotonin is made difficult both by issues of analytical specificity and sensitivity and by preanalytical issues of PPP sample preparation. The second, and in some ways greater, problem is the persistence over decades of a highly discrepant body of literature. This prevalence of discrepancy has led to the present 
Reviews situation, in which nearly all prior research on circulating free serotonin must be disregarded. A major contributor to this situation appears to be the failure of most of the investigators to diligently compare their results to previous work and their consequent failure to recognize the existence of problems and difficulties in this area. Although the analysis of PPP serotonin presents special problems and the reported concentrations vary widely, similar situations have occurred with several biochemical analytes. We are familiar with similar situations regarding the determination of concentrations of epinephrine, neuropeptide Y, oxytocin, and anadamide, among other neurohormonal analytes (116 ) .
In the absence of a governing authority, it is not a simple matter to rectify the general and apparently frequent problem of highly discrepant biomedical results or the specific problem regarding the measurement of PPP serotonin. Unfortunately, at present, there is little impetus or incentive to invest substantial effort in the proper validation and QC of assays used in biomedical research. We suggest that, in general, funding agencies should place a greater emphasis on the validation and quality assessment/control of analytical methods employed in funded studies. Journal editors and reviewers could also require more thorough method validation and appropriately extensive comparison to prior relevant reports.
Concerning the improvement of the accuracy and consistency of reported human PPP serotonin values, there is a clear and pressing need for a systematic interlaboratory approach to the problem. One particularly relevant model for efforts in this regard is the approach that was taken when similar problems were encountered in the measurement of plasma histamine (113 ) .
We hope that the present study will raise awareness of fundamental and persistent problems with plasma (PPP) serotonin measurement. Development of a reference method and elaboration of reference materials appear to be necessary steps if the situation is going to be rectified. Implementation of these steps might at first involve the interlaboratory measurement of PPP serotonin in carefully prepared 
